Skip to Content
Cancer Diagnosis Program
Contact NExT
Show menu
Search this site

Welcome to the Cancer Diagnosis Program!

The Cancer Diagnosis Program strives to improve the diagnosis and assessment of cancer by effectively moving new scientific knowledge into clinical practice. This national program stimulates, coordinates and funds resources and research for the development of innovative in vitro diagnostics, novel diagnostic technologies and appropriate human specimens in order to better characterize cancers and allow improved medical decision making and evaluation of response to treatment.

For more information about the Cancer Diagnosis Program and its Branches, please click here.

News and Announcements

06/2022
Visit this page to see the schedule of CDP and other DCTD programs presentations at 2022 ASCO.
03/2022
CDP’s Dr. Magdalena Thurin participated in ASCO/CAP Immune Checkpoint Inhibitor (ICI) Predictive Factor Virtual Summit in September 2021; slides and recordings are now available here. Exit Disclaimer
11/2021
In September, NCI hosted the FDA/NIH Next Generation Sequencing and Radiomics Workshop: Resource Requirements for Acceleration of Clinical Applications Including Artificial Intelligence.
10/2021
CDP's Dr. Brian Sorg is involved in a cross-agency collaboration with NASA, FDA, NIH, and HHS's BARDA that could lead to unprecedented advancements personalized medicine by extending the life of tissue chips.
09/2021
Dr. Lyndsay Harris, Associate Director of the CDP, commemorates the 50th anniversary of the National Cancer Act with a Staff Highlight in the DCTD newsletter on the evolution of cancer biomarkers, diagnostics, and where research is headed.
04/2021
Click here to see recordings and abstracts from presentations by CDP and other DCTD programs at 2021 AACR.